Literature DB >> 34315699

Fractures and Osteoporosis in Patients With Diabetes With Charcot Foot.

Oliver Christian Rabe1,2, Matilde Winther-Jensen2,3, Kristine Højgaard Allin2,3,4, Ole Lander Svendsen5,2,3,6.   

Abstract

OBJECTIVE: Charcot foot is a serious complication of diabetes, with degeneration of the bones and joints in the foot and ankle. It is unknown whether patients with diabetes with a Charcot foot have an increased risk of osteoporosis and fractures. The aim of this study was to investigate whether patients with diabetes with a Charcot foot have an increased risk of fracture and/or osteoporosis compared with patients with diabetes without Charcot foot. RESEARCH DESIGN AND METHODS: A Danish register-based, nationwide population-based matched cohort study was conducted. During 1995-2018, we identified 1,602 patients with diabetes with Charcot foot and matched them on sex and date of diagnosis of diabetes with 16,296 patients with diabetes without Charcot foot. We used logistic regression to estimate odds ratios (ORs) with 95% CIs for fracture and osteoporosis. Information about exposure, outcome, and comorbidities was retrieved from the Danish National Patient Register.
RESULTS: Diabetes patients with Charcot foot had higher risk of fractures compared with those without Charcot foot (i.e., ORs for any fracture, lower-leg fracture, foot fracture, and osteoporotic fracture were 1.8 [95% CI 1.6-2.0], 2.4 [2.0-2.8], 2.9 [2.6-3.3], and 1.3 [1.1-1.4], respectively). Furthermore, patients with diabetes with Charcot foot had higher risk of osteoporosis compared with the patients without Charcot foot, with an OR of 1.3 (95% CI 1.1-1.5).
CONCLUSIONS: Patients with diabetes with a Charcot foot have an increased risk of fractures and osteoporosis compared with patients with diabetes without a Charcot foot.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 34315699     DOI: 10.2337/dc21-0369

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  2 in total

1.  Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.

Authors:  Zhencheng Xiong; Ping Yi; Xiangsheng Tang; Li Shu; Chi Zhang
Journal:  Biomed Res Int       Date:  2022-02-07       Impact factor: 3.411

2.  Integrated Analysis of Crucial Genes and miRNAs Associated with Osteoporotic Fracture of Type 2 Diabetes.

Authors:  Liang Mo; Zhangzheng Wang; Haoran Huang; Jianxiong Li; Chao Ma; Jiahao Zhang; Fayi Huang; Wei He; Yuhao Liu; Chi Zhou
Journal:  Biomed Res Int       Date:  2022-08-10       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.